levoleucovorin and Cytomegalovirus-Infections

levoleucovorin has been researched along with Cytomegalovirus-Infections* in 5 studies

Other Studies

5 other study(ies) available for levoleucovorin and Cytomegalovirus-Infections

Article	Year
Disseminated strongyloidiasis and cytomegalovirus infection in a patient with anaplastic large cell lymphoma. Annals of hematology, 2007, Volume: 86, Issue:12 Topics: Adult; Albendazole; Anthelmintics; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; Cyclophosphamide; Cytomegalovirus Infections; Doxorubicin; Endemic Diseases; Ganciclovir; Gastritis; Humans; Immunocompromised Host; Immunosuppressive Agents; Leucovorin; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Oman; Prednisolone; Prednisone; Remission Induction; Strongyloidiasis; Vincristine	2007
[Secondary prevention of opportunistic infections in HIV-infected patients]. Revista clinica espanola, 2001, Volume: 201, Issue:2 Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Antiprotozoal Agents; Antitubercular Agents; Antiviral Agents; Clarithromycin; Cytomegalovirus Infections; Drug Therapy, Combination; Ethambutol; Ganciclovir; Humans; Leucovorin; Mycobacterium avium-intracellulare Infection; Pneumonia, Pneumocystis; Pyrimethamine; Recurrence; Rifabutin; Sulfadiazine; Sulfamethoxazole; Toxoplasmosis; Trimethoprim	2001
Cytomegalovirus enteritis after treatment with 5-fluorouracil, leukovorin, cisplatin, and alpha-interferon. The American journal of gastroenterology, 1995, Volume: 90, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytomegalovirus Infections; Enteritis; Esophageal Neoplasms; Fluorouracil; Humans; Ileitis; Interferon-alpha; Leucovorin; Male; Middle Aged	1995
Preventing opportunistic infections. PI perspective, 1995, Issue:no 16 As more drugs are approved for the prevention of opportunistic infections, concerns regarding the benefits and potential risks of these therapies are arising. A synopsis of the data for prophylaxis against opportunistic infections is provided for the following: Pneumocystis carinii pneumonia, fungal infections, Mycobacterium avium complex, cytomegalovirus infections, and toxoplasmosis. General precautions in using preventive medications for people with fewer than 100 CD4 plus cells are highlighted. Topics: Acyclovir; AIDS-Related Opportunistic Infections; Clarithromycin; Clindamycin; Clinical Trials as Topic; Clotrimazole; Cytomegalovirus Infections; Dapsone; Fluconazole; Ganciclovir; Humans; Itraconazole; Leucovorin; Mycobacterium avium-intracellulare Infection; Mycoses; Pentamidine; Pneumonia, Pneumocystis; Pyrimethamine; Rifabutin; Toxoplasmosis; Trimethoprim, Sulfamethoxazole Drug Combination; Valacyclovir; Valine	1995
FDA's newly designated treatment INDs. JAMA, 1988, Jul-08, Volume: 260, Issue:2 Topics: Clinical Protocols; Cytomegalovirus; Cytomegalovirus Infections; Drug Combinations; Drug Therapy, Combination; Glucuronates; Humans; Immune Sera; Immunoglobulins; Immunoglobulins, Intravenous; Kidney Transplantation; Leucovorin; Pneumonia, Pneumocystis; Quinazolines; Trimetrexate; United States; United States Food and Drug Administration	1988